An NIH-funded study used the 1972 rise in the UK school-leaving age as a natural experiment. Among more than 100,000 UK Biobank participants, the extra year of school lowered dementia diagnoses, most among those at high genetic risk.
The UK's AD-SMART trial tests several Alzheimer's drugs against one placebo group, starting with metformin and atomoxetine. Its design could more than halve the time to evaluate treatments. It aims to recruit 1,200 people.
A large Danish study found that people who started statins within a year of a type 2 diabetes diagnosis had a 15 percent lower relative risk of dementia over the next decade than those who never started treatment.